The New Frontier of Solid Tumor TCEs: Achieving High Potency & Safety with B7-H7 Targeting
- B7-H7 is broadly upregulated across multiple high-prevalence malignancies with significant unmet need, while maintaining a restricted and favorable expression profile in healthy tissue
- NextPoint lead T-cell engager, NPX372, features an optimized molecular architecture specifically designed to achieve an expansive therapeutic index
- Leveraging a biomarker-driven patient selection strategy and validated preclinical safety data, a streamlined Phase I clinical program has been launched